Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ: ALNY )

251.08 +8.47 (+3.49%)
Streaming Delayed Price Updated: 2:08 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
How Do Investors Really Feel About Alnylam Pharmaceuticals?
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Is Alnylam Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Via Benzinga
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
FDA Approves Sanofi's Hemophilia Drug
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year. 
Via Benzinga
Exposures Product Safety
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
Alnylam's Amvuttra wins FDA approval for ATTR-CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity. 
Via Benzinga
Exposures Product Safety
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views
Via Benzinga
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Best performing large-cap stocks last week: Alnylam Pharma up 16%, Roku up 14%, Elbit Systems up 13%, Venture Global up 12%, Boeing up 11%. Are they in your portfolio? 
Via Benzinga
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
Via Investor's Business Daily
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
Alnylam's Amvuttra receives FDA approval for ATTR-CM, expanding its use and securing broad insurance coverage as global regulatory reviews continue. 
Via Benzinga
Exposures Product Safety
How Do Investors Really Feel About Alnylam Pharmaceuticals?
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Via Benzinga
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Alnylam Delivers a Big Q4 Earnings Beat
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress. 
Via The Motley Fool
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.